AISF PRACTICE GUIDANCE ON PHARMACOLOGICAL TREATMENT OF METABOLIC-DYSFUNCTION ASSOCIATED STEATOTIC LIVER DISEASE AND STEATOHEPATITIS (MASLD/MASH): A 2026 UPDATE

Descargar Publicación
Incretin and Glucagon Signalling in MASLD and MASH: Integrating Metabolic Pathways With Disease Progression Resmetirom: An Update on Therapy for Metabolic Dysfunction-Associated Steatohepatitis (MASH)